J
Jonathan Polikoff
Researcher at Kaiser Permanente
Publications - 67
Citations - 9247
Jonathan Polikoff is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Docetaxel & Lenalidomide. The author has an hindex of 28, co-authored 65 publications receiving 7546 citations. Previous affiliations of Jonathan Polikoff include MedStar Washington Hospital Center & New York University.
Papers
More filters
Journal ArticleDOI
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer,Fabrice Barlesi,Daniel Waterkamp,Keunchil Park,Fortunato Ciardiello,Joachim von Pawel,Shirish M. Gadgeel,Toyoaki Hida,Dariusz M. Kowalski,Manuel Cobo Dols,Diego Cortinovis,Joseph W. Leach,Jonathan Polikoff,Carlos H. Barrios,Fairooz F. Kabbinavar,Osvaldo Arén Frontera,Filippo de Marinis,Hande Turna,Jong Seok Lee,Marcus Ballinger,Marcin Kowanetz,Pei He,Daniel S. Chen,Alan Sandler,David R. Gandara +24 more
TL;DR: Overall survival was significantly longer with atezolizumab in the ITT and PD-L1-expression populations, and overall survival improvement was similar in patients with squamous non-squamous lung cancer.
Journal ArticleDOI
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P. DeMatteo,Karla V. Ballman,Cristina R. Antonescu,Robert G. Maki,Peter W.T. Pisters,George D. Demetri,Martin E. Blackstein,Charles D. Blanke,Margaret von Mehren,Murray F. Brennan,Shreyaskumar Patel,Martin D. McCarter,Jonathan Polikoff,Benjamin R. Tan,Kouros Owzar +14 more
TL;DR: Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour.
Journal ArticleDOI
Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
Tomasz M. Beer,Eugene D. Kwon,Charles G. Drake,Karim Fizazi,Christopher J. Logothetis,Gwenaelle Gravis,Vinod Ganju,Jonathan Polikoff,Fred Saad,Piotr Humanski,Josep M. Piulats,Pablo González Mella,Siobhan Ng,Dirk Jaeger,Francis Parnis,Fabio Franke,J. Puente,Roman Carvajal,Lisa Sengeløv,M. Brent McHenry,Arvind Varma,Alfonsus J. M. van den Eertwegh,Winald R. Gerritsen +22 more
TL;DR: Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer and the observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.
Journal ArticleDOI
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai,Anh Tran,Phioanh L. Nghiemphu,Whitney B. Pope,Orestes E. Solis,Michael T. Selch,Emese Filka,William H. Yong,Paul S. Mischel,Linda M. Liau,Surasak Phuphanich,Keith L. Black,Scott Peak,Richard M. Green,Cynthia E. Spier,Tatjana Kolevska,Jonathan Polikoff,Louis Fehrenbacher,Robert Elashoff,Timothy F. Cloughesy +19 more
TL;DR: Comparative subset analysis showed that poor prognosis patients (recursive partitioning analysis class V/VI) may derive an early benefit from the use of first-line BV and TMZ during and after RT showed improved PFS without improved OS compared to the University of California, Los Angeles/KPLA control group.
Journal ArticleDOI
Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Edward H. Romond,Jong-Hyeon Jeong,Priya Rastogi,Sandra M. Swain,Charles E. Geyer,Michael S. Ewer,Vikas Rathi,Louis Fehrenbacher,Adam Brufsky,Catherine A. Azar,Patrick J. Flynn,John L. Zapas,Jonathan Polikoff,Howard M. Gross,David D. Biggs,James N. Atkins,Elizabeth Tan-Chiu,Ping Zheng,Greg Yothers,Eleftherios P. Mamounas,Norman Wolmark +20 more
TL;DR: The risk versus benefit of trastuzumab as given in this regimen remains strongly in favor of trastsine, especially when the treatment regimen includes anthracycline-related decline in cardiac function.